US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Silexion Therapeutics Corp

2.55

-0.2100-7.61%

Post-market: 2.50-0.0500-1.96%17:27 EST

Volume:57.73K

Turnover:152.62K

Market Cap:7.97M

PE:-0.01

High:2.88

Open:2.88

Low:2.44

Close:2.76

52wk High:63.45

52wk Low:2.13

Shares:3.13M

Float Shares:2.75M

Volume Ratio:0.67

T/O Rate:2.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-395.3595

EPS(LYR):-395.3595

ROE:--

ROA:-193.54%

PB:-2.00

PE(LYR):-0.01

Loading ...

Overview Company News Filings

BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical

Silexion Therapeutics Corp - on Track to Initiate Phase 2/3 Trial in H1 2026

THOMSON REUTERS

Silexion Therapeutics Corp - Regulatory Submissions in Israel by Q4 2025, Germany by Q1 2026

THOMSON REUTERS

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Silexion Therapeutics Unveils Gene Silencing Breakthroughs Targeting KRAS-Driven Cancers

BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026

Silexion Therapeutics completes toxicology studies for SIL204

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Maxim Group Remains a Buy on Silexion Therapeutics (SLXN)

Silexion Therapeutics Corp : Maxim Group Cuts Target Price to $12 From $24

THOMSON REUTERS

Silexion Therapeutics reports third quarter net loss of $7.5 million and cash balance of $9.2 million

Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)

Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types

BUZZ-Silexion Therapeutics climbs on promising cancer drug data

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-Kras Activity of Sil204, Demonstrating up to 99.7% Inhibition and First Evidence in Gastric Cancer

THOMSON REUTERS

BRIEF-Silexion Therapeutics Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing

Silexion Therapeutics Files for $100 Million Mixed Shelf Offering

MT Newswires Live

Silexion Therapeutics files $100M mixed securities shelf

Silexion Therapeutics Corp Files for Mixed Shelf of up to $100 Mln - SEC Filing

THOMSON REUTERS

Silexion Therapeutics Corp. Announces At-The-Market Offering Agreement for up to $13.17 Million in Ordinary Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLXN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":2.55,"timestamp":1764709200000,"preClose":2.76,"halted":0,"volume":57730,"hourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.55,"latestTime":"17:27 EST","volume":14,"amount":35.2000012,"timestamp":1764714437609},"delay":0,"floatShares":2753490,"shares":3126642,"eps":-395.35947,"marketStatus":"Post-Mkt","change":-0.21,"latestTime":"12-02 18:18:08 EST","open":2.88,"high":2.88,"low":2.44,"amount":152621.3783,"amplitude":0.15942,"askPrice":2.81,"askSize":100,"bidPrice":2.49,"bidSize":202,"shortable":0,"etf":0,"ttmEps":-395.35947,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":2.76,"preHourTrading":{"tag":"盘前","latestPrice":2.87,"preClose":2.76,"latestTime":"09:29 EST","volume":2753,"amount":7895.051472900001,"timestamp":1764685799999},"postHourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.55,"latestTime":"17:27 EST","volume":14,"amount":35.2000012,"timestamp":1764714437609},"volumeRatio":0.666831},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":2753490,"roa":"-193.54%","roe":"--","lyrEps":-395.359461,"volumeRatio":0.666831,"shares":3126642,"dividePrice":0,"high":2.88,"amplitude":0.15942,"preClose":2.76,"low":2.44,"week52Low":2.13,"pbRate":"-2.00","week52High":63.45,"institutionHeld":0,"latestPrice":2.55,"committee":0.337748,"eps":-395.35947,"divideRate":0,"volume":57730,"delay":0,"ttmEps":-395.35947,"open":2.88,"prevYearClose":30.15,"prevWeekClose":2.83,"prevMonthClose":2.83,"prevQuarterClose":3.4,"fiveDayClose":2.23,"twentyDayClose":3.17,"sixtyDayClose":7.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730610000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2025-12-01","current":-0.006576,"percent":0.926667,"low":-0.532214,"twenty":-0.466609,"median":-0.25519,"eighty":-0.120089,"high":-0.075397,"avg":-0.291854,"sd":0.158934,"marketCap":1587556},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-01","current":-0.096549,"twenty":-0.466609,"median":-0.25519,"eighty":-0.120089,"marketCap":1587556}],"updateTime":1764690151350},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588056944","title":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056944","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056944?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:55","pubTimestamp":1764683748,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical Dec 2 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS RECEIVES P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2588053763","title":"Silexion Therapeutics Corp - on Track to Initiate Phase 2/3 Trial in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053763?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2588053083","title":"Silexion Therapeutics Corp - Regulatory Submissions in Israel by Q4 2025, Germany by Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053083?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2588537080","title":"Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588537080","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588537080?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680400,"startTime":"0","endTime":"0","summary":"Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the en","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197820/0/en/Silexion-Therapeutics-Receives-Positive-Feedback-from-German-Health-Authority-on-Design-of-Phase-2-3-Clinical-Trial-in-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139","SLXN"],"gpt_icon":0},{"id":"2588298081","title":"Silexion Therapeutics Unveils Gene Silencing Breakthroughs Targeting KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588298081","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588298081?lang=en_us&edition=fundamental","pubTime":"2025-12-02 13:50","pubTimestamp":1764654605,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has released a corporate presentation detailing its progress in developing RNA silencing treatments targeting mutated KRAS proteins, which are key drivers in several aggressive cancers, including pancreatic, colorectal, lung, small bowel, and appendix cancers. The company's first-generation product, Loder, demonstrated a survival benefit in clinical studies for patients with mutant KRAS-driven locally advanced pancreatic cancer. In these studies, patients receiving Loder in combination with standard-of-care chemotherapy showed a median overall survival of 22.7 months compared to 13.4 months for those on chemotherapy alone. Silexion's second-generation siRNA candidate, SIL204, is designed to enhance cellular delivery, improve stability, and offer broader antitumor activity. The platform supports both intratumor and systemic administration, aiming to treat both primary tumors and metastases. Preclinical results with SIL204 indicate potential applicability for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL8XhCx5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2586899470","title":"BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2586899470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586899470?lang=en_us&edition=fundamental","pubTime":"2025-11-26 00:46","pubTimestamp":1764089197,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026Nov 25 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS SUCCESSFULLY COMPLETES TOXICOLOGY STUDIES FOR SI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA2RTPS9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2586471301","title":"Silexion Therapeutics completes toxicology studies for SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2586471301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586471301?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:20","pubTimestamp":1764080440,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced the successful completion of toxicology studies for SIL204, the Company’s next-generation RNA silencing ther...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-completes-toxicology-studies-for-sil204-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-completes-toxicology-studies-for-sil204-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA","SLXN","BK4539","IE0009354923.USD","BK4007","BK4588","BK4139","LENZ","BK4585","BK4505"],"gpt_icon":0},{"id":"2586479668","title":"Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479668","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479668?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:15","pubTimestamp":1764080100,"startTime":"0","endTime":"0","summary":"Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194426/0/en/Silexion-Therapeutics-Successfully-Completes-Toxicology-Studies-for-SIL204-Next-Generation-RNA-Silencing-Therapy-Ahead-of-Phase-2-3-Clinical-Trial-in-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RNA","BK4007","SLXN","IE0009354923.USD","BK4505","BK4588","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2583507226","title":"Maxim Group Remains a Buy on Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583507226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583507226?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:15","pubTimestamp":1763133336,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Naz Rahman reiterated a Buy rating on Silexion Therapeutics yesterday and set a price target of $12.00. According to TipRanks, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-silexion-therapeutics-slxn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-silexion-therapeutics-slxn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2583887591","title":"Silexion Therapeutics Corp : Maxim Group Cuts Target Price to $12 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2583887591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583887591?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:54","pubTimestamp":1763045663,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2582372172","title":"Silexion Therapeutics reports third quarter net loss of $7.5 million and cash balance of $9.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372172","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372172?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:07","pubTimestamp":1762956470,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. reported a net loss of $7.5 million, or  per share, for the nine months ended September 30, 2025, compared to a net loss of $14.8 million, or  per share, for the same period in 2024, reflecting a 49.3% decrease. Cash and cash equivalents increased to $9.2 million as of September 30, 2025, from $1.2 million at December 31, 2024. Shareholders' equity improved to $7.0 million from a capital deficiency of $4.0 million at the end of 2024. The company completed a public offering and received proceeds from warrant exercises totaling approximately $9.5 million during the third quarter. Silexion regained full compliance with Nasdaq listing requirements in September 2025. Business developments included new preclinical data for SIL204 and preparations for Phase 2/3 clinical trial initiation in the first half of 2026, with ongoing regulatory submissions in Israel and the EU.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2DTyQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2578506665","title":"Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578506665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578506665?lang=en_us&edition=fundamental","pubTime":"2025-10-25 23:55","pubTimestamp":1761407713,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics, with a price target of $24.00. The co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-silexion-therapeutics-slxn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-silexion-therapeutics-slxn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN"],"gpt_icon":0},{"id":"2571328485","title":"Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types","url":"https://stock-news.laohu8.com/highlight/detail?id=2571328485","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571328485?lang=en_us&edition=fundamental","pubTime":"2025-09-30 21:06","pubTimestamp":1759237595,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL8725M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2571328352","title":"BUZZ-Silexion Therapeutics climbs on promising cancer drug data","url":"https://stock-news.laohu8.com/highlight/detail?id=2571328352","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571328352?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:59","pubTimestamp":1759237185,"startTime":"0","endTime":"0","summary":"BUZZ-Silexion Therapeutics climbs on promising cancer drug data** Shares of drug developer Silexion Therapeutics SLXN.O rise 11% to $3.75 premarket** Says its experimental cancer drug, SIL204, showed strong activity in lab tests, targeting a wide range of KRAS mutations linked to aggressive cancers** Reports inhibition rates between 83.5% and 99.7% in 11 human cancer cell lines, including its first data in gastric cancer and expanded results in colorectal cancer** SIL204 also showed high potency against the G12R mutation, which affects about 17% of pancreatic cancer patients** Plans to start mid-to-late stage trials in the first half of 2026** As of last close, stock down 88% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nL3N3VH0YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2571347020","title":"Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-Kras Activity of Sil204, Demonstrating up to 99.7% Inhibition and First Evidence in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2571347020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571347020?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:40","pubTimestamp":1759236000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUA9KSJDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2570783830","title":"BRIEF-Silexion Therapeutics Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2570783830","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570783830?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:37","pubTimestamp":1758922650,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Corp Files For Mixed Shelf Of Up To $100 Million - SEC FilingSept 26  - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS CORP FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILINGSource text: [ID:n0001178913-25-003388]Further company coverage: SLXN.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nFWN3VD13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2570983796","title":"Silexion Therapeutics Files for $100 Million Mixed Shelf Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2570983796","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570983796?lang=en_us&edition=fundamental","pubTime":"2025-09-27 04:51","pubTimestamp":1758919912,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) on Friday reported a mixed shelf offering, worth $100 million, by which it will sell its ordinary shares, warrants and units overtime.Shares of the biotech company closed around 2% lower on Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","SLXN","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2570837316","title":"Silexion Therapeutics files $100M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2570837316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570837316?lang=en_us&edition=fundamental","pubTime":"2025-09-27 04:35","pubTimestamp":1758918921,"startTime":"0","endTime":"0","summary":"16:32 EDT Silexion Therapeutics (SLXN) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-100m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-100m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","SLXN","BK4007"],"gpt_icon":0},{"id":"2570322748","title":"Silexion Therapeutics Corp Files for Mixed Shelf of up to $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2570322748","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570322748?lang=en_us&edition=fundamental","pubTime":"2025-09-27 04:32","pubTimestamp":1758918736,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nFWN3VD13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2570832843","title":"Silexion Therapeutics Corp. Announces At-The-Market Offering Agreement for up to $13.17 Million in Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2570832843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570832843?lang=en_us&edition=fundamental","pubTime":"2025-09-27 04:06","pubTimestamp":1758917207,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to offer and sell up to $13.17 million of its ordinary shares through Wainwright as sales agent. The shares will be sold from time to time at prevailing market prices under a shelf registration statement on Form S-3, once declared effective by the SEC. Wainwright will receive a 3% commission on the gross sales price of any shares sold, and Silexion has agreed to reimburse certain expenses and provide customary indemnification. The company is not required to sell any shares under the agreement, and the offering will terminate upon the sale of all shares or termination of the agreement by either party.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL6T9NPr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}]}}